Anthony Leung, DO
Infectious Disease · Akron, OHNPI 1245252667
Payments from drug & device makers
Across 169 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$871
- Johnson & Johnson$655
- Merck$376
- AbbVie$343
- Viiv Healthcare Company$298
- Janssen Products, LP$255
- plus $412 from 8 others
What the payments were for
- Food & beverage$2,88190%
- Education$32810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 51 | $871 |
| Johnson & Johnson | 33 | $655 |
| Merck | 20 | $376 |
| AbbVie(2 entities) | 19 | $343 |
| Viiv Healthcare Company | 20 | $298 |
| Janssen Products, LP | 3 | $255 |
| Astellas Pharma US Inc | 6 | $132 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $107 |
| Cumberland Pharmaceuticals, Inc. | 4 | $62 |
| Napo Pharmaceuticals Inc | 2 | $29 |
| Mayne Pharma Commercial LLC | 2 | $26 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Romark Laboratories, LC | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,209 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 18 | $4,545 |
| Vancomycin Hcl | 17 | $3,926 |
| Entecavir | 19 | $1,301 |
| Ethambutol Hcl | 11 | $552 |
| Cefazolin Sodium | 11 | $505 |
| CeftriaxoneCeftriaxone Sodium | 11 | $369 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $311 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Akron
- Michael TanAkron$160K
- Thomas FileAkron$68K
- Robert SalataCleveland$2.8M
- Carl FichtenbaumCincinnati$1.6M
- Curtis DonskeyCleveland$1.6M
- Moises Huaman JooCincinnati$1.2M
- Robin JumpCleveland$1.2M
- Grace McComseyCleveland$1M
- Robert BonomoCleveland$1M
- Ian BairdColumbus$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.